scholarly journals Triage of HR-HPV Positive Women with Minor Cytological Abnormalities: A Comparison of mRNA Testing, HPV DNA Testing, and Repeat Cytology Using a 4-Year Follow-Up of a Population-Based Study

PLoS ONE ◽  
2014 ◽  
Vol 9 (2) ◽  
pp. e90023 ◽  
Author(s):  
Maria Persson ◽  
K. Miriam Elfström ◽  
Sophia Brismar Wendel ◽  
Elisabete Weiderpass ◽  
Sonia Andersson
2008 ◽  
Vol 122 (12) ◽  
pp. 2835-2841 ◽  
Author(s):  
Angel Chao ◽  
Kuang-Hung Hsu ◽  
Chyong-Huey Lai ◽  
Huei-Jean Huang ◽  
Swei Hsueh ◽  
...  

2013 ◽  
Vol 3 (1) ◽  
pp. 182-189 ◽  
Author(s):  
Elisabeth B. Budal ◽  
Hans K. Haugland ◽  
Robert Skar ◽  
Bjørn O. Maehle ◽  
Tone Bjørge ◽  
...  

2012 ◽  
Vol 106 (5) ◽  
pp. 975-981 ◽  
Author(s):  
D C Rijkaart ◽  
J Berkhof ◽  
F J van Kemenade ◽  
V M H Coupe ◽  
L Rozendaal ◽  
...  

2012 ◽  
Vol 1 (1) ◽  
pp. S40
Author(s):  
Marilyn Dawlett ◽  
Teresa Kologinczak ◽  
Jian-Ping Wang ◽  
Nour Sneige ◽  
Therese Bevers ◽  
...  

2008 ◽  
Vol 6 (1) ◽  
pp. 58 ◽  
Author(s):  
_ _

Cervical carcinoma remains a health issue for women worldwide. Cervical cytology screening is the current method for early detection, and the NCCN Cervical Cancer Screening Clinical Practice Guidelines in Oncology provide direction for evaluating and managing this process, including clarified and revised recommendations on screening techniques and intervals and follow-up of abnormal screening results, including colposcopy. Human papillomavirus (HPV) DNA testing for primary cervical cancer has been approved by the FDA, and HPV DNA testing for high-risk virus types can also be used as a component of both primary screening and workup of abnormal cytology results. Colposcopy, along with colposcopically directed biopsies, has become the primary method for evaluating women with abnormal cervical cytologies. Special considerations for colposcopy performed during pregnancy are also discussed. For the most recent version of the guidelines, please visit NCCN.org


2016 ◽  
Vol 17 (5) ◽  
pp. 750 ◽  
Author(s):  
Alex Vorsters ◽  
Severien Van Keer ◽  
Samantha Biesmans ◽  
Annick Hens ◽  
Ilse De Coster ◽  
...  

2017 ◽  
Vol 61 (3) ◽  
pp. 230-236 ◽  
Author(s):  
Peter Ziemke

Objective: Immunochemical detection of the protein p16INK4a in cervical cytology is used in combination with Ki-67. Cells positive for both proteins are certain to have been transformed by high-risk HPV. p16/Ki-67 immunocytochemistry provides a significant improvement in specificity over cytology and HPV DNA testing. However, p16/Ki-67 immunocytochemistry also has its limitations. Study Design: The research is based on the follow-up of 1,131 patients for whom p16/Ki-67 immunocytochemistry was performed with cytology. Dependencies on the age of patients with LSIL, number of p16/Ki-67-positive cells, and different results during repeated examinations were analyzed. Results: In LSIL, positive p16/Ki-67 is less specific for ≥CIN2/HSIL for patients younger than 30 years compared to patients aged 30 years or older (61.1 vs. 75.7%, p < 0.013). Using a score of 10 p16/Ki-67-marked cells as a positive result instead of 1 led to significantly higher specificity (89.0 vs. 70.2%, p < 0.001). This modified threshold offers better risk assessment in LSIL. In repeated immunocytochemical investigations, 28.4% of the results deviated from the first examination. Conclusion: The abovementioned discrepancies can be interpreted as hints about the molecular biological causes of suboptimal performance of p16/Ki-67. An efficient and reliable application of p16/Ki-67 immunocytochemistry requires knowledge of its methodological limitations.


2011 ◽  
Vol 47 (6) ◽  
pp. 864-871 ◽  
Author(s):  
Henry C. Kitchener ◽  
Clare Gilham ◽  
Alexandra Sargent ◽  
Andrew Bailey ◽  
Rebecca Albrow ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document